Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Trial Profile

Phase I Study of Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Interleukin-15 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Nov 2018 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
    • 27 Nov 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
    • 05 Jun 2018 According to trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology, currently cohort A has enrolled 1 to 3 planned patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top